Hunan Warrant Pharmaceutical Co., Ltd. (688799.SH) Latest Company News

Oct 30, 2026, 09:11 UTC
Hunan Warna Pharmaceutical plans to acquire a 30% stake in Hunan Dingbang Isotope Pharmaceutical Technology for RMB 16.75 million from Hunan Queshan Tiaowang Venture Capital Partnership.
Source:
- finance.sina.cn
Oct 30, 2026, 09:09 UTC
Hunan Warner Pharmaceutical reported revenue of 967 million yuan and net profit attributable to shareholders of 82.7937 million yuan for the first three quarters of 2026.
Source:
- finance.sina.cn
Oct 30, 2026, 09:09 UTC
Hunan Warner Pharmaceutical reported third-quarter 2026 revenue of 306 million yuan, down 17.80% year over year, and net profit attributable to shareholders of 18.1939 million yuan, down 86.62%.
Source:
- finance.sina.cn
Oct 17, 2026, 07:50 UTC
China's National Medical Products Administration approved Hunan Huanar Pharmaceutical Chiral Medicine Co.'s applications to market terbutaline sulfate and indocyanine green as active pharmaceutical ingredients for use in domestic formulations.
Source:
- finance.sina.cn
Oct 16, 2026, 11:28 UTC
China’s National Medical Products Administration approved Hunan Warrant Pharmaceutical Chiral Pharmaceutical Co.’s application to market indocyanine green active pharmaceutical ingredient for use in domestic formulations, with a joint review result of A.
Source:
- finance.sina.cn
Sep 29, 2026, 09:09 UTC
Hunan Warrant Pharmaceutical received a drug registration certificate from the National Medical Products Administration for its 25mg Iguratimod tablets, a Class 4 chemical drug for active rheumatoid arthritis, deemed to have passed consistency evaluation.
Source:
- finance.sina.cn
Sep 17, 2026, 09:18 UTC
Hunan Huana Pharmaceutical Investment Partnership (Limited Partnership), controlling shareholder of Huana Pharmaceutical, sold 1.38 million shares via block trade on September 17, 2026, reducing its and concert parties' combined stake from 39.09% to 38.06%.
Source:
- finance.sina.cn
- finance.sina.cn
Aug 31, 2026, 11:20 UTC
Warner Pharmaceutical received a drug registration certificate approved by the National Medical Products Administration for Loxoprofen Sodium Patch, used for anti-inflammatory and analgesic purposes, available in two specifications.
Source:
- finance.sina.cn
Aug 24, 2026, 10:46 UTC
Hua Na Pharmaceutical increased the investment budget for its wholly-owned subsidiary Zhigen Pharmaceutical's Phase I high-end API and intermediate green manufacturing base project from no more than 650 million yuan to no more than 800 million yuan.
Source:
- finance.sina.cn
Jul 17, 2026, 07:59 UTC
Hunan Warner Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration for a supplementary application to change the marketing authorization holder of Hydroxychloroquine Sulfate Tablets.
Source:
- finance.sina.cn

688799.SH

Hunan Warna Pharmaceutical plans to acquire a 30% stake in Hunan Dingbang Isotope Pharmaceutical Technology for RMB 16.75 million from Hunan Queshan Tiaowang Venture Capital Partnership.

Hunan Warner Pharmaceutical reported revenue of 967 million yuan and net profit attributable to shareholders of 82.7937 million yuan for the first three quarters of 2026.

Hunan Warner Pharmaceutical reported third-quarter 2026 revenue of 306 million yuan, down 17.80% year over year, and net profit attributable to shareholders of 18.1939 million yuan, down 86.62%.

China's National Medical Products Administration approved Hunan Huanar Pharmaceutical Chiral Medicine Co.'s applications to market terbutaline sulfate and indocyanine green as active pharmaceutical ingredients for use in domestic formulations.

China’s National Medical Products Administration approved Hunan Warrant Pharmaceutical Chiral Pharmaceutical Co.’s application to market indocyanine green active pharmaceutical ingredient for use in domestic formulations, with a joint review result of A.

Hunan Warrant Pharmaceutical received a drug registration certificate from the National Medical Products Administration for its 25mg Iguratimod tablets, a Class 4 chemical drug for active rheumatoid arthritis, deemed to have passed consistency evaluation.

Hunan Huana Pharmaceutical Investment Partnership (Limited Partnership), controlling shareholder of Huana Pharmaceutical, sold 1.38 million shares via block trade on September 17, 2026, reducing its and concert parties' combined stake from 39.09% to 38.06%.

Warner Pharmaceutical received a drug registration certificate approved by the National Medical Products Administration for Loxoprofen Sodium Patch, used for anti-inflammatory and analgesic purposes, available in two specifications.

Hua Na Pharmaceutical increased the investment budget for its wholly-owned subsidiary Zhigen Pharmaceutical's Phase I high-end API and intermediate green manufacturing base project from no more than 650 million yuan to no more than 800 million yuan.

Hunan Warner Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration for a supplementary application to change the marketing authorization holder of Hydroxychloroquine Sulfate Tablets.